Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial

医学 哮喘 恶化 安慰剂 屋尘螨 不利影响 过敏 随机对照试验 随机化 过敏原 临床终点 内科学 皮质类固醇 免疫学 替代医学 病理
作者
Alan B. Goldsobel
出处
期刊:Pediatrics [American Academy of Pediatrics]
卷期号:140 (Supplement_3): S210-S210 被引量:54
标识
DOI:10.1542/peds.2017-2475nnn
摘要

To evaluate the efficacy and adverse events of 2 doses of house dust mite (HDM) sublingual allergen immunotherapy (SLIT) versus a placebo for asthma exacerbations during inhaled corticosteroid (ICS) reduction in cases of unstable asthma.A total of 834 subjects (99% white, mean age of 33 years [range of 17–83 years], 48% women) were randomized 1:1:1 to receive 2 HDM tablet doses or a placebo. Six hundred ninety-three participants completed the trial. Dropout rates were similar among the 3 treatment groups.This was a double-blind, placebo-controlled, randomized trial comparing HDM SLIT using daily tablets in 2 doses (6 SQ-HDM or 12 SQ-HDM) with using a matching placebo. All subjects had HDM-related asthma and allergic rhinitis for >1 year, a positive skin prick test to HDM, and detectable HDM-specific serum IgE. All subjects had partly controlled (72%) or uncontrolled (28%) asthma (per a prespecified GINA algorithm) on ICS (400–1200 mcg budesonide equivalent) at inclusion. At randomization, 1 of the 3 study treatments was added for 7–12 months depending on the date of entry. During the last 6 months of the treatment period, the daily ICS dose was reduced by 50% for 3 months and subsequently withdrawn from the subjects who did not experience an asthma exacerbation. The primary end point, the time to the first moderate or severe asthma exacerbation, was measured from the start of the ICS reduction period until the first exacerbation. Secondary end points included asthma quality of life measurements and adverse events.Both doses of HDM SLIT tablets significantly reduced the risk of a moderate or severe asthma exacerbation compared with the placebo (hazard ratio [HR] 0.72 for the 6 SQ-HDM group [95% CI, 0.52–0.99], P = .045; and HR 0.69 for the 12 HDM-SQ group [95% CI, 0.50–0.96], P = .03). There was no significant difference between the 2 active-treatment groups (HR 0.96; P = .84). The absolute risk for the first asthma exacerbation was 26% (n = 62) for the 6 SQ-HDM group, 24% (n = 59) for the 12 SQ-HDM group, and 32% (n = 83) for the placebo group, primarily involving moderate rather than severe exacerbations and with no significant difference between the 2 active-treatment groups. There was no significant difference in the change in quality of life for either active-treatment group. Local treatment-related adverse events were common in both active-treatment doses. There were no reports of anaphylaxis.This is the first published controlled trial to show that patients with HDM-related asthma whose symptoms were not well controlled with ICS can achieve significant improvement in asthma control with HDM SLIT during ICS reduction. The absolute reduction after 6 months of treatment was 10%, primarily due to an effect on moderate exacerbations.This is a unique study showing that HDM SLIT is associated with a modest reduction in asthma exacerbations in adult patients with poorly controlled HDM-related asthma, even with ICS reduction. In March 2017, HDM SLIT tablets were approved by the FDA for use for AR in the United States by patients ages 18–65 years. In the European Union, HDM SLIT tablets are approved for use in children.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
酷波er的应助被gyyyyy采纳,获得10
1秒前
啦啦啦发布了新的文献求助10
1秒前
1秒前
搜集达人的应助被大意的访旋采纳,获得10
1秒前
田浩阳发布了新的文献求助10
2秒前
2秒前
3秒前
doctordu发布了新的文献求助10
3秒前
3秒前
3秒前
4秒前
4秒前
偏偏发布了新的文献求助10
4秒前
Code_king发布了新的文献求助10
5秒前
Code_king发布了新的文献求助10
5秒前
Code_king发布了新的文献求助10
5秒前
5秒前
5秒前
ss发布了新的文献求助10
5秒前
珍妮发布了新的文献求助10
5秒前
zhaizhai完成签到,获得积分10
5秒前
5秒前
我是老大的应助被dmmmm0903采纳,获得10
5秒前
张亚慧发布了新的文献求助10
6秒前
6秒前
腹黑同学完成签到,获得积分10
6秒前
6秒前
xfk完成签到,获得积分10
7秒前
Haruhi发布了新的文献求助10
7秒前
略略略完成签到,获得积分10
8秒前
梦里潇湘完成签到 ,获得积分10
8秒前
8秒前
水厂小白发布了新的文献求助10
8秒前
粉色热狗发布了新的文献求助10
8秒前
整齐善斓发布了新的文献求助10
9秒前
9秒前
小蘑菇的应助被田浩阳采纳,获得10
9秒前
咸鱼发布了新的文献求助10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177464
求助须知:如何正确求助?哪些是违规求助? 9568344
关于积分的说明 21798806
捐赠科研通 7772101
什么是DOI,文献DOI怎么找? 3432346
关于科研通互助平台的介绍 2556593
邀请新用户注册赠送积分活动 2477882